^
Association details:
| Biomarker: | MAP2K1 mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers
Published date:
10/23/2020
Excerpt:
Patients who received NGS-guided therapy exhibited higher OS (not achieved vs. 6.5 months, p < 0.001) and ORR (87.5% vs. 25%, p < 0.001) than those without targetable mutations and who received first-line chemotherapy. BTCs harboring mutations in IDH1, ATM/BRCA2, or MAP2K1/BRAF (V600E) received treatment with dasatinib, olaparib, or trametinib, respectively....All these patients achieved complete response or partial response.
DOI:
https://doi.org/10.1007/s00262-020-02745-y
